RJA
CRDL

Raymond James & Associates’s Cardiol Therapeutics CRDL Stock Holding History

Raymond James & Associates’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,154
Closed -$20.2K – 3987
2024
Q1 		$20.2K Hold
11,154
– – ﹤0.01% 3872
2023
Q4 		$9.4K Buy
+11,154
New +$9.48K ﹤0.01% 3798

Other funds holding CRDL

TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
LSA
Lion Street Advisors Austin, Texas $289M AUM 3.13% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return
MOS
MGO One Seven Beachwood, Ohio $4.98B AUM 22.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Raymond James & Associates's CRDL Position: Q2 2024 in Review

Raymond James & Associates sold out of Cardiol Therapeutics (CRDL) in Q2 2024, closing a stake of 11,154 shares — an estimated $20.2K sold.

Raymond James & Associates first reported a position in CRDL in Q4 2023 and held it in 2 quarters. The position peaked at $20.2K in Q1 2024. 41 funds tracked by Wall St. Rank hold CRDL as of Q2 2024.

  • Raymond James & Associates reported no remaining Cardiol Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Raymond James & Associates sold 11,154 Cardiol Therapeutics shares in Q2 2024, an estimated $20.2K.
  • Raymond James & Associates first reported a position in Cardiol Therapeutics in Q4 2023 and held it in 2 quarters.
  • Raymond James & Associates's Cardiol Therapeutics position peaked at $20.2K in Q1 2024.
  • 41 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q2 2024.

Based on Raymond James & Associates's 13F filing for Q2 2024, filed 19 Jul 2024.